tirzepatide cvot results An Observational Study of Cardiovascular Outcomes of vs Glucagon-Like Peptide-1 Receptor Agonists Tirzepatide Matches Dulaglutide in Large

Spatial Metabolomics Reveals How Tirzepatide Inhibits Colorectal Cancer via Glucose Metabolic Reprogramming We are excited to share a recent publication in Advanced Science titled The Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide Attenuates Colon Cancer Development by Regulating Glucose Metabolism. In this study, the authors employed spatial metabolomics services provided by MetwareBio to explore the metabolic mechanisms by which tirzepatide (TZP)a dual GIP and GLP-1 receptor agonist initially approved for type 2 diabetesexerts potent anti-tumor effects in colorectal cancer (CRC)

The dosing device is typically a prefilled pen

Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves ophthalmopathy: results of a prospective, single-blind, randomized study

High costs and high demand for weight loss drugs have left payers struggling to balance coverage considerations with budget impacts